Connection
Marc Bonaca to Risk Factors
This is a "connection" page, showing publications Marc Bonaca has written about Risk Factors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.803 |
|
|
|
-
Aboyans V, Canonico ME, Chastaingt L, Anand SS, Brodmann M, Couffinhal T, Criqui MH, Debus ES, Mazzolai L, McDermott MM, Bonaca MP. Peripheral artery disease. Nat Rev Dis Primers. 2025 Sep 18; 11(1):68.
Score: 0.089
-
McDermott MM, Kadian-Dodov D, Aronow HA, Beckman JA, Bolden DM, Castro-Dominguez YS, Creager MA, Criqui MH, Goodney PP, Gornik HL, Hamburg NM, Leeper NJ, Olin JW, Ross E, Bonaca MP. Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine. Vasc Med. 2025 06; 30(3):367-383.
Score: 0.087
-
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
Score: 0.085
-
Hogan SE, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation. 2024 02 20; 149(8):635-637.
Score: 0.080
-
McDermott MM, Ho KJ, Alabi O, Criqui MH, Goodney P, Hamburg N, McNeal DM, Pollak A, Smolderen KG, Bonaca M. Disparities in Diagnosis, Treatment, and?Outcomes of Peripheral Artery?Disease: JACC Scientific Statement. J Am Coll Cardiol. 2023 12 12; 82(24):2312-2328.
Score: 0.079
-
Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med. 2023 06; 28(3):233-235.
Score: 0.075
-
Hess CN, Bonaca MP. Guideline-Directed Medical Therapy in?PAD: Time to Step on the Gas. JACC Cardiovasc Interv. 2023 02 13; 16(3):344-346.
Score: 0.074
-
Bonaca MP, Hogan SE. Tradeoffs in Approach to PAD?Revascularization: Shared Decision Making in the Spotlight. J Am Coll Cardiol. 2023 01 31; 81(4):371-373.
Score: 0.074
-
Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur Heart J. 2022 12 21; 43(48):5037-5044.
Score: 0.074
-
Bonaca MP, Reece TB. The prognostic implications of cardiac troponin in Type A aortic dissection and the challenge of understanding therapeutic consequences. Eur Heart J Acute Cardiovasc Care. 2022 08 09; 11(8):607-608.
Score: 0.072
-
Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2?P-TIMI 50 trial. Clin Cardiol. 2022 Aug; 45(8):831-838.
Score: 0.072
-
Behan SA, Mulder H, Rockhold FW, Gutierrez JA, Baumgartner I, Katona BG, Mahaffey KW, Norgren L, Jones S, Bonaca MP. Impact of Polyvascular Disease and Diabetes on?Limb and Cardiovascular Risk in Peripheral Artery Disease. J Am Coll Cardiol. 2022 05 03; 79(17):1781-1783.
Score: 0.071
-
Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021 06 11; 128(12):1868-1884.
Score: 0.066
-
Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
Score: 0.065
-
Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokg?zoglu L, Bonaca MP. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021 02; 319:51-61.
Score: 0.065
-
Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. J Med Econ. 2021 Jan-Dec; 24(1):402-409.
Score: 0.064
-
Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
Score: 0.063
-
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M, Kamensky G, Isaza D, Aylward P, Johanson P, Bonaca MP. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 05 18; 9(10):e015785.
Score: 0.062
-
Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
Score: 0.060
-
Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Curr Cardiol Rep. 2020 Jan 29; 22(3):13.
Score: 0.060
-
Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2?P-TIMI 50 trial. Vasc Med. 2019 04; 24(2):159-161.
Score: 0.057
-
Bonaca MP. Polyvascular disease and risk: When two is not better than one. Vasc Med. 2018 12; 23(6):531-533.
Score: 0.055
-
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 01 23; 137(4):338-350.
Score: 0.052
-
Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MP. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation. 2018 02 13; 137(7):684-692.
Score: 0.052
-
Cavallari I, Bonaca MP. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. Interv Cardiol Clin. 2017 01; 6(1):119-129.
Score: 0.049
-
Bonaca MP. Antithrombotic Therapy in Patients With Peripheral Artery Disease. JAMA Cardiol. 2016 10 01; 1(7):803-804.
Score: 0.048
-
Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, L?pez-Send?n J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 07; 37(14):1133-42.
Score: 0.045
-
Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, Im K, Aylward P, Ardissino D, Isaza D, Parkhomenko A, Goudev AR, Dellborg M, Kontny F, Corbalan R, Medina F, Jensen EC, Held P, Braunwald E, Sabatine MS, Bonaca MP. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016 Jan 21; 37(4):400-8.
Score: 0.045
-
Bonaca MP, O'Malley RG, Murphy SA, Jarolim P, Conrad MJ, Braunwald E, Sabatine MS, Morrow DA. Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):431-40.
Score: 0.042
-
Bonaca MP, O'Gara PT. Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer. Curr Cardiol Rep. 2014; 16(10):536.
Score: 0.040
-
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
Score: 0.037
-
Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31; 125(4):577-83.
Score: 0.034
-
Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.
Score: 0.032
-
Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, Jarolim P, Braunwald E, Morrow DA. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010 May 11; 55(19):2118-24.
Score: 0.031
-
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 01; 99(3):344-8.
Score: 0.024
-
Nurmohamed NS, Ngo-Metzger Q, Taub PR, Ray KK, Figtree GA, Bonaca MP, Hsia JA, Angadageri S, Earls JP, Rodriguez F, Sandhu AT, Min JK, Hoffmann U, Maron DJ, Bhatt DL. First myocardial infarction: risk factors, symptoms, and medical therapy. Eur Heart J. 2025 Oct 07; 46(38):3762-3772.
Score: 0.022
-
Walker M, Riggs KA, Rohatgi A, Beckman J, Addo T, Girotra S, Bonaca MP, Armstrong E, Kumbhani DJ. Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions. J Am Heart Assoc. 2025 Oct 07; 14(19):e039734.
Score: 0.022
-
Haller PM, Melloni GEM, Berg DD, Kamanu FK, Lai YP, Antman EM, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O'Donoghue ML, Scirica BM, Wiviott SD, Chasman D, Everett BM, Braunwald E, Morrow DA, Ridker PM, Ellinor PT, Sabatine MS, Ruff CT, Marston NA. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. J Am Coll Cardiol. 2025 Sep 23; 86(12):860-873.
Score: 0.022
-
Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, Bejjani A, Khairani CD, Davies J, Porio N, Assi AA, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq Z, Wei E, Zuluaga-S?nchez V, Zarghami M, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Campia U, Bikdeli B, Piazza G. Predictors of venous thromboembolic events in hospitalized patients with COVID-19. J Thromb Thrombolysis. 2025 Apr; 58(4):485-496.
Score: 0.021
-
Goldenberg NA, Schulman S, Kittelson JM, Abshire TC, Casella JF, Dale R, Halperin JL, Hanson J, Kessler CM, Manco-Johnson MJ, McDevitt L, Sidonio RF, Spyropoulos AC, Steg PG, Bonaca MP. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. J Thromb Haemost. 2025 Feb; 23(2):651-656.
Score: 0.021
-
Fowler X, Mehta K, Eid M, Gladders B, Kearing S, Moore KO, Creager MA, Austin AM, Feinberg MW, Bonaca MP, Greenland P, McDermott MM, Goodney PP. Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease. Vasc Med. 2024 12; 29(6):653-663.
Score: 0.021
-
Marston NA, Pirruccello JP, Melloni GEM, Kamanu F, Bonaca MP, Giugliano RP, Scirica BM, Wiviott SD, Bhatt DL, Steg PG, Raz I, Braunwald E, Libby P, Ellinor PT, Bick AG, Sabatine MS, Ruff CT. Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials. Nat Med. 2024 Sep; 30(9):2641-2647.
Score: 0.021
-
Ponukumati AS, Krafcik BM, Newton L, Baribeau V, Mao J, Zhou W, Goodney EJ, Fowler XP, Eid MA, Moore KO, Armstrong DG, Feinberg MW, Bonaca MP, Creager MA, Goodney PP. Association between tissue loss type and amputation risk among Medicare patients with concomitant diabetes and peripheral arterial disease. J Vasc Surg. 2024 Nov; 80(5):1543-1552.e12.
Score: 0.020
-
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024 05 02; 390(17):1560-1571.
Score: 0.020
-
Bikdeli B, Krishnathasan D, Khairani CD, Bejjani A, Davies J, Porio N, Tristani A, Armero A, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Ortiz-Rios MD, Zuluaga-S?nchez V, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Grandone E, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Lan Z, Piazza G. Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19. Thromb Res. 2024 05; 237:209-215.
Score: 0.020
-
Small AM, Melloni GEM, Kamanu FK, Bergmark BA, Bonaca MP, O'Donoghue ML, Giugliano RP, Scirica BM, Bhatt D, Antman EM, Raz I, Wiviott SD, Truong B, Wilson PWF, Cho K, O'Donnell CJ, Braunwald E, Lubitz SA, Ellinor P, Peloso GM, Ruff CT, Sabatine MS, Natarajan P, Marston NA. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis. JAMA Cardiol. 2024 Apr 01; 9(4):357-366.
Score: 0.020
-
Farber A, Menard MT, Bonaca MP, Bradbury A, Conte MS, Debus ES, Eldrup N, Goodney P, Gupta PC, Hinchliffe RJ, Houlind KC, Kolh P, Kum SWC, Nordanstig J, Parikh SA, Patel MR, Patrone L, Sillesen H, Strong MB, Varcoe RL, Vega de Ceniga M, Venermo MA, Rosenfield K. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. Br J Surg. 2024 01 31; 111(2).
Score: 0.020
-
Fowler XP, Eid MA, Barnes JA, Gladders B, Austin AM, Goodney EJ, Moore KO, Kearing S, Feinberg MW, Bonaca MP, Creager MA, Goodney PP. Trends of Concomitant Diabetes and Peripheral Artery Disease and Lower Extremity Amputation in US Medicare Patients, 2007 to 2019. Circ Cardiovasc Qual Outcomes. 2023 06; 16(6):e009531.
Score: 0.019
-
Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O'Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MS. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 01 21; 44(4):293-300.
Score: 0.019
-
Marston NA, Garfinkel AC, Kamanu FK, Melloni GM, Roselli C, Jarolim P, Berg DD, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O'Donoghue ML, Raz I, Scirica BM, Braunwald E, Morrow DA, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023 01 14; 44(3):221-231.
Score: 0.019
-
Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
Score: 0.018
-
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thromb Haemost. 2021 12; 121(12):1684-1695.
Score: 0.017
-
Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2?P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.
Score: 0.016
-
Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
Score: 0.016
-
Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
Score: 0.016
-
Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.
Score: 0.016
-
Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 05 18; 9(10):e015331.
Score: 0.015
-
Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin L. No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.
Score: 0.015
-
Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 05 19; 141(20):1600-1607.
Score: 0.015
-
Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 10 01; 5(4):200-206.
Score: 0.015
-
Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, Bedimo RJ, Butt AA, Marconi VC, Sico JJ, Tindle HA, Bonaca MP, Aday AW, Freiberg MS. Microvascular Disease, Peripheral Artery Disease, and Amputation. Circulation. 2019 08 06; 140(6):449-458.
Score: 0.015
-
Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park JG, Bonaca MP, Scirica BM, Morrow DA. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Clin Chem Lab Med. 2019 06 26; 57(7):1084-1092.
Score: 0.014
-
Puymirat E, Bonaca M, Iliou MC, Tea V, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevallereau P, Taldir G, Bataille V, Ferri?res J, Schiele F, Simon T, Danchin N. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. Arch Cardiovasc Dis. 2019 Aug - Sep; 112(8-9):459-468.
Score: 0.014
-
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536.
Score: 0.014
-
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527.
Score: 0.014
-
Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 01 15; 139(3):366-375.
Score: 0.014
-
Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferri?res J, Schiele F, Simon T, Danchin N. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol. 2019 Feb; 42(2):227-234.
Score: 0.014
-
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 12; 19(12):1579-1589.
Score: 0.014
-
Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferri?res J, Schiele F, Simon T, Danchin N, Puymirat E. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. Eur J Prev Cardiol. 2019 03; 26(4):411-419.
Score: 0.014
-
Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019 01 01; 123(1):145-152.
Score: 0.014
-
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 09 20; 379(12):1107-1117.
Score: 0.014
-
Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD. DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018 05; 20(5):1102-1110.
Score: 0.013
-
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 06; 200:83-89.
Score: 0.013
-
Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, Armstrong EJ, Giri J, Bonaca MP, Pradhan A, Bavry AA, Kumbhani DJ. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2017 04 10; 10(7):712-724.
Score: 0.012
-
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017 05 03; 117(5):940-947.
Score: 0.012
-
Isselbacher EM, Bonaca MP, Di Eusanio M, Froehlich J, Bossone E, Sechtem U, Pyeritz R, Patel H, Khoynezhad A, Eckstein HH, Jondeau G, Ramponi F, Abbasi M, Montgomery D, Nienaber CA, Eagle K, Lindsay ME. Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection. Circulation. 2016 10 04; 134(14):1013-1024.
Score: 0.012
-
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
Score: 0.011
-
O'Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, Braunwald E, Morrow DA. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.
Score: 0.010
-
Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
Score: 0.009
-
Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DA. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012 Aug; 34(2):222-8.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|